ストックスクリーナーアプリを入手
1.47
2.78%
0.03
前日終値:
$1.44
開ける：
$1.44
24時間の取引高:
8.65M
Relative Volume:
0.56
時価総額：
$949.45M
収益：
$196.12M
当期純損益:
$-69.59M
株価収益率:
-14.09
EPS:
-0.1043
ネットキャッシュフロー:
$-126.13M
1週間 パフォーマンス:
+15.62%
1か月 パフォーマンス:
+26.50%
6か月 パフォーマンス:
+8.03%
1年 パフォーマンス:
+8.03%
1日の値動き範囲:
$1.41
$1.50
1週間の範囲:
$1.26
$1.50
52週間の値動き範囲:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
名前
Geron Corp
セクター
電話
(650) 473-7700
住所
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.48 | 923.79M | 196.12M | -69.59M | -126.13M | -0.1043 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Goldman | Sell |
| 2025-05-08 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | 開始されました | Leerink Partners | Outperform |
| 2024-04-30 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | 開始されました | TD Cowen | Buy |
| 2024-03-15 | 繰り返されました | Needham | Buy |
| 2023-09-12 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-28 | 開始されました | Goldman | Neutral |
| 2022-10-28 | 開始されました | Wedbush | Outperform |
| 2022-07-28 | 再開されました | B. Riley Securities | Buy |
| 2021-11-02 | 開始されました | Robert W. Baird | Outperform |
| 2021-02-18 | 再開されました | B. Riley Securities | Buy |
| 2020-08-03 | 開始されました | Stifel | Buy |
| 2019-11-19 | 再開されました | B. Riley FBR | Buy |
| 2019-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-04-09 | アップグレード | Needham | Hold → Buy |
| 2019-01-31 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | 繰り返されました | FBR & Co. | Outperform |
| 2016-09-13 | 繰り返されました | FBR Capital | Outperform |
| 2015-12-07 | 繰り返されました | Piper Jaffray | Overweight |
| 2015-04-21 | 開始されました | Oppenheimer | Outperform |
| 2014-06-12 | アップグレード | MLV & Co | Hold → Buy |
| 2014-03-12 | ダウングレード | MLV & Co | Buy → Hold |
| 2013-12-10 | 繰り返されました | MLV & Co | Buy |
| 2013-12-10 | アップグレード | Needham | Hold → Buy |
| 2013-11-08 | 繰り返されました | MLV & Co | Buy |
| 2013-10-16 | 開始されました | MLV & Co | Buy |
| 2012-08-30 | 開始されました | Stifel Nicolaus | Buy |
| 2012-06-28 | 開始されました | Needham | Hold |
すべてを表示
Geron Corp (GERN) 最新ニュース
Geron stock leans on its myelofibrosis story - AD HOC NEWS
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Form 4 Geron Corporation For: 1 July By Investing.com - Investing.com Canada
Geron (GERN) director Robert J. Spiegel receives 6,103-share stock grant for board fees - Stock Titan
Why Did GERN Stock Tumble 10% Pre-Market Today? - Stocktwits
GERN Forecast — Price Target — Prediction for 2027 - TradingView
Geron (GERN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
GERON CORP (GERN) Stock Chart - ChartMill
Geron Corp (GERN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Geron Corp (GERN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Geron Corp (GERN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Geron Corp (GERN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Geron Corp (GERN) Institutional Confidence - TradingKey
Geron Corp (GERN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GERN Stock Builds Momentum On Strong RYTELO Data - StocksToTrade
Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch - Ad-hoc-news.de
GERN: RYTELO’s expanding use and strong clinical data drive steady growth and future pipeline potential - TradingView
Earnings call transcript: Geron Q1 2026 shows revenue growth, stock rises - Investing.com
Geron Corp stock (US3741631036): Focus on valuation as short interest eases - AD HOC NEWS
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN) - Yahoo Finance
GERN SEC FilingsGeron Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
Geron: Time To Reconsider This Oversold Biotech (NASDAQ:GERN) - Seeking Alpha
1GERN.MI Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (BIT:1GERN) - ChartMill
Geron Shareholders Expand Equity Plan and Elect Directors - The Globe and Mail
Geron (NASDAQ: GERN) adds 4.5M shares to 2018 equity incentive plan - Stock Titan
Geron (NASDAQ: GERN) director awarded 220,000 options at $1.26 strike - Stock Titan
Geron (NASDAQ: GERN) director awarded stock options for 220,000 shares at $1.26 - Stock Titan
Geron (GERN) awards director Susan Molineaux 220,000 stock options - Stock Titan
Geron (GERN) director granted 220,000 stock options at $1.26 - Stock Titan
Geron (GERN) director Dawn Carter Bir awarded 220,000 stock options - Stock Titan
GERNGeron Corp Stock Price and Quote - Finviz
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
GERN: All proposals passed; clinical and commercial strategies advancing, with key trial data ahead - TradingView
Geron Corporation’s SWOT analysis: biotech stock faces sales headwinds - Investing.com
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo! Finance Canada
Geron Corp stock (US3741631036): new stock option grants keep hiring momentum in focus - AD HOC NEWS
Five new Geron hires receive options for 333,750 shares - Stock Titan
Shareholders of Geron Corporation Should Contact The Gross Law F - GuruFocus
GERN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Deep Track (GERN) reports 31.7M shares, 4.95% ownership (May 2026) - Stock Titan
TradingKey - TradingKey
Geron reports Q1 revenue growth and updates on blood cancer drug progress. - Pluang
Geron Corporation Announces Positive Real-World Evidence Study of RYTELO® in Lower-Risk Myelodysplastic Syndromes Ahead of EHA 2026 Presentations - Quiver Quantitative
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 - ChartMill
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy? - Insider Monkey
10 Best US Stocks Under $5 to Buy - Insider Monkey
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Geron Corp (GERN) 財務データ
収益
当期純利益
現金流量
EPS
Geron Corp (GERN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER |
Feb 18 '26 |
Sale |
1.94 |
9,855 |
19,119 |
17,645 |
1.21%
3.14%
大文字化:
|
ボリューム (24 時間):